3-hydroxy-4-methoxybenzaldehyde thio semicarbazone | 14453-26-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 3-hydroxy-4-methoxybenzaldehyde thio semicarbazone
• 英文别名: Hydrazinecarbothioamide, 2-[(3-hydroxy-4-methoxyphenyl)methylene]-；[(3-hydroxy-4-methoxyphenyl)methylideneamino]thiourea
• CAS: 14453-26-0
• 化学式: C₉H₁₁N₃O₂S
• mdl: MFCD00556249
• 分子量: 225.271
• InChiKey: ARINKVDYBABITQ-UHFFFAOYSA-N

物化性质

• 熔点：
  176-177 °C(Solv: ethanol (64-17-5))
• 沸点：
  414.5±55.0 °C(Predicted)
• 密度：
  1.35±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  112
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-氯乙酰乙酸乙酯 、 3-hydroxy-4-methoxybenzaldehyde thio semicarbazone 以 乙醇 为溶剂， 生成 ethyl 2-[2-[(3-hydroxy-4-methoxyphenyl)methylidene]hydrazinyl]-4-methyl-1,3-thiazole-5-carboxylate
  参考文献：
  名称：

  In vitro and in silico antimalarial activity of 2-(2-hydrazinyl)thiazole derivatives

  摘要：

  A series of 2-(2-hydrazinyl)thiazole derivatives with a wide range of substitutions at 2-, 4- and 5-positions were synthesized, characterized and evaluated their inhibitory potentials against plasmodium falciparum, NF54, by in vitro blood stage assay. The compounds, ethyl-4-methyl-2-[(E)-2-[1-(pyridin-2-yl)ethylidene]hydrazin-1-yl]-1,3-thiazole-5-carboxylate, 4d, and 1-(4-methyl-2-[(E)-2-[1-(pyridin-2-yl)ethylidenelhydrazin-1-yl]-mu 3-thiazol-5-yliethan-1-one, 5d showed significant antimalarial activity with IC50 values of 0.725 mu M and 0.648 mu M respectively. To understand the mechanism, the binding interactions between 2-(2-hydrazinyl)thiazole derivatives and trans-2-enoyl acyl carrier protein reductase of P. falciparum were studied through docking studies. The half maximal inhibitory concentration (IC50) through docking studies for the compounds, 4d and 5d were found to be 22.88 mu M and 631.84 mu M respectively. (C) 2013 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.ejps.2013.11.001
• 作为产物：
  描述：

  异香兰素 、 氨基硫脲 以 乙醇 为溶剂， 反应 3.0h， 生成 3-hydroxy-4-methoxybenzaldehyde thio semicarbazone
  参考文献：
  名称：

  作为阿尔茨海默病抗胆碱酯酶药物的噻唑类似物的设计、合成和构效关系

  摘要：

  痴呆症是一种通常与阿尔茨海默病 (AD) 相关的神经系统疾病，并且在许多其他中枢神经系统 (CNS) 疾病中也可见到。有限数量的药物不足以提供足够的缓解以提高患有这种症状的患者的生活质量；因此，应仔细评估所有治疗选择。在这项研究中，基于胆碱能假设设计和合成了新的噻唑基腙衍生物（2a-2l）。它们的化学结构已通过 1H NMR、13C NMR 和 HRMS 光谱技术确认。使用QikProp 4.8软件预测合成化合物的ADME（吸收、分布、代谢、消除）参数。结论是所有化合物都表现出令人满意的类药物特性。此外，还通过改进的 Ellman 分光光度法测试了它们在体外对乙酰胆碱酯酶 (AChE) 和丁酰胆碱酯酶 (BChE) 的抑制活性。结果表明，所有化合物对BChE均表现出较弱的抑制作用。另一方面，大部分化合物（2a、2b、2d、2e、2g、2i和2j）具有一定的AChE抑制活性，计算其IC50值为0

  DOI：

  10.3390/molecules25184312

文献信息

• Discovery of Novel Bromophenol–Thiosemicarbazone Hybrids as Potent Selective Inhibitors of Poly(ADP-ribose) Polymerase-1 (PARP-1) for Use in Cancer
  作者：Chuanlong Guo、Lijun Wang、Xiuxue Li、Shuaiyu Wang、Xuemin Yu、Kuo Xu、Yue Zhao、Jiao Luo、Xiangqian Li、Bo Jiang、Dayong Shi

  DOI：10.1021/acs.jmedchem.8b01946

  日期：2019.3.28

  Poly(ADP-ribose) polymerase-1 (PARP-1) is a new potential target for anticancer drug discovery. A series of bromophenol-thiosemicarbazone hybrids as PARP-1 inhibitors were designed, synthesized, and evaluated for their antitumor activities. Among them, the most promising compound, 11, showed excellent selective PARP-1 inhibitory activity (IC50 = 29.5 nM) over PARP-2 (IC50 > 1000 nM) and potent anticancer

  聚（ADP-核糖）聚合酶-1（PARP-1）是抗癌药物发现的新潜在目标。设计，合成并评估了一系列作为PARP-1抑制剂的溴酚-硫代半碳杂zone杂化物的抗肿瘤活性。其中，最有前途的化合物11对PARP-2（IC50> 1000 nM）表现出优异的选择性PARP-1抑制活性（IC50 = 29.5 nM），并对SK-OV-3，Bel-7402和在体内SK-OV-3细胞异种移植模型中，HepG2癌细胞系（IC50 = 2.39、5.45和4.60μM）以及肿瘤生长的抑制作用。进一步的研究表明，化合物11通过多种抗癌机制发挥了抗肿瘤作用，包括诱导凋亡和细胞周期停滞，DNA双链断裂的细胞蓄积，DNA修复改变，抑制H2O2触发的PARylation，通过产生细胞毒性活性氧而产生的抗增殖作用以及自噬。另外，化合物11显示出良好的药代动力学特性和良好的安全性。这些观察表明，化合物11可以用作发现新的抗癌药物的先导化合物。
• Synthesis, anti-bacterial and anti-fungal activities of some novel Schiff bases containing 2,4-disubstituted thiazole ring
  作者：S.K. Bharti、G. Nath、R. Tilak、S.K. Singh

  DOI：10.1016/j.ejmech.2009.11.008

  日期：2010.2

  antimicrobial activities. The structures of synthesized compounds were established by spectroscopic (FT-IR, 1H NMR, 13C NMR, Mass) and elemental analyses. Both the anti-bacterial and anti-fungal activities with MIC values of compounds were evaluated. The results of anti-bacterial screening reveal that among all the compounds screened eight compounds showed moderate to good anti-bacterial activity while ten

  一系列的亚芳基-2-（4-（4-（4-甲氧基/溴苯基）噻唑-2-基）肼（4a – z）和1-（4-（4-甲氧基/溴苯基）噻唑-2-基）-2合成了-cyclohexydenne / cyclopentylidene肼（5a – b / 6a – b），并对其抗菌性能进行了表征和筛选。通过光谱（FT-IR，1 H NMR，1313 C NMR，质量）和元素分析。用化合物的MIC值评估了抗菌和抗真菌活性。抗菌筛选结果表明，在筛选出的所有化合物中，有八种化合物表现出中等至良好的抗菌活性，而新合成的化合物中有十种表现出良好至优异的抗真菌活性。在测试的化合物中，MIC值在6.25–25μg/ ml范围内的最有效化合物是针对三种真菌菌株viz的4a，4n，4z，5a，5b，6a和6b。白色念珠菌，新型隐球菌和黄曲霉。
• Synthesis, Antileishmanial Activity and in silico Studies of Aminoguanidine Hydrazones (AGH) and Thiosemicarbazones (TSC) Against Leishmania chagasi Amastigotes
  作者：Thiago M. de Aquino、Paulo H. B. França、Érica E. E. S. Rodrigues、Igor. J.S. Nascimento、Paulo F. S. Santos-Júnior、Pedro G. V. Aquino、Mariana S. Santos、Aline C. Queiroz、Morgana V. Araújo、Magna S. Alexandre-Moreira、Raiza R. L. Rodrigues、Klinger A. F. Rodrigues、Johnnatan D. Freitas、Jacques Bricard、Mario R. Meneghetti、Jean-Jacques Bourguignon、Martine Schmitt、Edeildo F. da Silva-Júnior、João X. de Araújo-Júnior

  DOI：10.2174/1573406417666210216154428

  日期：2022.2

  Leishmaniasis is a worldwide health problem, highly endemic in developing countries. Among the four main clinical forms of the disease, visceral leishmaniasis is the most severe, fatal in 95% of cases. The undesired side-effects from first-line chemotherapy and the reported drug resistance search for effective drugs that can replace or supplement those currently used an urgent need. Aminoguanidine hydrazones (AGH's) have been explored for exhibiting a diverse spectrum of biological activities, in particular the antileishmanial activity of MGBG. The bioisosteres thiosemicarbazones (TSC's) offer a similar biological activity diversity, including antiprotozoal effects against Leishmania species and Trypanosoma cruzi.

  Considering the impact of leishmaniasis worldwide, this work aimed to design, synthesize, and perform a screening upon L. chagasi amastigotes and for the cytotoxicity of the small "in-house" library of both AGH and TSC derivatives and their structurally-related compounds.

  A set of AGH's (3-7), TSC's (9, 10), and semicarbazones (11) were initially synthesized. Subsequently, different semi-constrained analogs were designed and also prepared, including thiazolidines (12), dihydrothiazines (13), imidazolines (15), pyrimidines (16, 18) azines (19, 20), and benzotriazepinones (23-25). All intermediates and target compounds were obtained with satisfactory yields and exhibited spectral data consistent with their structures. All final compounds were evaluated against L. chagasi amastigotes and J774.A1 cell line. Molecular docking was performed towards trypanothione reductase using GOLD® software.

  The AGH's 3i, 4a, and 5d, and the TSC's 9i, 9k, and 9o were selected as valuable hits. These compounds presented antileishmanial activity compared with pentamidine, showing IC50 values ranged from 0.6 to 7.27 μM, maximal effects up to 55.3%, and satisfactory SI values (ranged from 11 to 87). On the other hand, most of the resulting semi-constrained analogs were found cytotoxic or presented reduced antileishmanial activity. In general, TSC class is more promising than its isosteric AGH analogs, and the beneficial aromatic substituent effects are not similar in both series. In silico studies have suggested that these hits are capable of inhibiting the trypanothione reductase from the amastigote forms.

  The promising antileishmanial activity of three AGH’s and three TSC’s was characterized. These compounds presented antileishmanial activity compared with PTD, showing IC50 values ranged from 0.6 to 7.27 μM, and satisfactory SI values. Further pharmacological assays involving other Leishmania strains are under progress, which will help to choose the best hits for in vivo experiments.

  背景：利什曼病是全球性健康问题，在发展中国家高度流行。在该病的四种主要临床形式中，内脏利什曼病是最严重的，95%的病例会致命。由于一线化疗药物的不良副作用和报道的药物耐药性，迫切需要寻找可以替代或补充当前使用的有效药物。氨基胍脒肼酮（AGH）已被探索用于展示多样的生物活性，特别是MGBG的抗利什曼病活性。生物同功异构体硫脲半胱氨酮（TSC）提供类似的生物活性多样性，包括对利什曼病和克氏锥虫的抗原虫效应。 目的：考虑到利什曼病在全球范围内的影响，本研究旨在设计、合成并对L. chagasi阿马斯蒂果虫进行筛选，以及对小型“内部”AGH和TSC衍生物及其结构相关化合物的细胞毒性进行评估。 方法：首先合成了一组AGH（3-7）、TSC（9, 10）和半胱氨酮（11）。随后，设计并制备了不同的半约束类似物，包括噻唑烷（12）、二氢噻嗪（13）、咪唑烷（15）、嘧啶（16, 18）、吲哚烷（19, 20）和苯并三唑环酮（23-25）。所有中间体和目标化合物均以满意的收率获得，并展示了与其结构一致的光谱数据。所有最终化合物均对L. chagasi阿马斯蒂果虫和J774.A1细胞系进行了评估。使用GOLD®软件对其进行了针对巯基还原酶的分子对接。 结果：AGH的3i、4a和5d以及TSC的9i、9k和9o被选为有价值的命中物。这些化合物与五环胺相比具有抗利什曼病活性，IC50值范围从0.6到7.27μM，最大效果高达55.3％，满意的SI值（范围从11到87）。另一方面，大多数结果的半约束类似物被发现具有细胞毒性或具有降低的抗利什曼病活性。总体而言，TSC类比其同功异构AGH类更有前景，而有益的芳香族取代作用在两个系列中并不相似。计算机模拟研究表明这些命中物能够抑制阿马斯蒂果虫的巯基还原酶。 结论：三种AGH和三种TSC的有前景的抗利什曼病活性得到了表征。这些化合物与PTD相比具有抗利什曼病活性，IC50值范围从0.6到7.27μM，SI值满意。正在进行涉及其他利什曼病菌株的进一步药理学评估，这将有助于选择最佳的命中物进行体内实验。
• Design, synthesis and biological assessment of new selective COX-2 inhibitors including methyl sulfonyl moiety
  作者：Begüm Nurpelin Sağlık、Derya Osmaniye、Serkan Levent、Ulviye Acar Çevik、Betül Kaya Çavuşoğlu、Yusuf Özkay、Zafer Asım Kaplancıklı

  DOI：10.1016/j.ejmech.2020.112918

  日期：2021.1

  Nonsteroidal anti-inflammatory drugs (NSAIDs) cause peptic lesions in the gastrointestinal mucosa by inhibiting the cyclooxygenase-1 (COX-1) enzyme. Selective COX-2 inhibition causes decreased side effects over current NSAIDs. Therefore, the studies about selective inhibition of COX-2 enzyme are very important for new drug development. The design, synthesis and biological activity evaluation of novel

  非甾体类抗炎药（NSAIDs）通过抑制环氧合酶1（COX-1）引起胃肠道粘膜消化性损伤。与目前的NSAID相比，选择性的COX-2抑制作用可减少副作用。因此，关于选择性抑制COX-2酶的研究对于新药开发非常重要。本文旨在设计，合成具有噻唑基肼-甲基磺酰基部分作为选择性COX-2抑制剂的新型衍生物，并对其进行生物活性评估。使用不同的光谱技术（例如1 H-NMR，13 C-NMR和HRMS）指定合成化合物的结构。此外，所有化合物的ADME参数估算均使用计算机模拟处理。评价体外COX-1 / COX-2酶抑制率是按照所述荧光法施加。根据酶抑制结果，合成的化合物显示出对COX-2酶抑制的选择性。化合物3a，3e，3f，3g，3i和3j表现出显着的COX-2抑制能力。其中，发现化合物3a是最有效的衍生物，IC 50值为0.140±0.006μM。此外，可以看出，化合物3a的抑制曲线比尼美舒利（IC 50）至少强12倍=
• 香草醛及其异构体在制备NA抑制剂中的应用
  申请人：湖南大学

  公开号：CN107987033B

  公开（公告）日：2020-04-24

  本发明涉及基于香草醛及其异构体，构建的式Ⅰ所示的含有羟基和甲氧基的2‑(2‑苄亚肼基)‑5‑酰基噻唑及其药学上可接受的盐，药物组合物以及其在制备流感病毒神经氨酸酶抑制剂中的应用。采用香草醛及其异构体作为原料，制备含有羟基和甲氧基的2‑(2‑苄亚肼基)‑5‑酰基噻唑：其中，R选自：甲基、乙基、C3～C4直链或C3～C4支链烷基；R1选自：氢、C1～C2烷基、C3～C4直链或C3～C4支链烷基、氟甲基、二氟甲基、三氟甲基、溴甲基、二溴甲基、三溴甲基、氯甲基、二氯甲基或三氯甲基；Y＝2‑羟基‑3‑甲氧基、2‑羟基‑4‑甲氧基、2‑羟基‑5‑甲氧基、2‑羟基‑6‑甲氧基、3‑羟基‑2‑甲氧基、3‑羟基‑4‑甲氧基、3‑羟基‑5‑甲氧基、3‑羟基‑6‑甲氧基、4‑羟基‑2‑甲氧基或4‑羟基‑3‑甲氧基。